Accretive Wealth Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$3.4M |
| 2 |
Humana
HUM
|
+$1.19M |
| 3 |
VeriSign
VRSN
|
+$1.13M |
| 4 |
Chevron
CVX
|
+$1.11M |
| 5 |
Microsoft
MSFT
|
+$744K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$1.36M |
| 2 |
State Street SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
|
+$872K |
| 3 |
Rollins
ROL
|
+$732K |
| 4 |
Marathon Petroleum
MPC
|
+$73K |
| 5 |
TransDigm Group
TDG
|
+$63K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 12.02% |
| 2 | Financials | 7.26% |
| 3 | Consumer Discretionary | 5.85% |
| 4 | Industrials | 5.48% |
| 5 | Communication Services | 4.48% |
Similar funds
Accretive Wealth Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Accretive Wealth Partners held 141 positions worth $226M, up 8.6% from $208M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Accretive Wealth Partners deployed $11.2M of net new capital in Q1 2024, opening 11 new positions and adding to 68 existing holdings. Its largest new stake was Humana: 3,149 shares worth $1.01M.
By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 11% a quarter earlier, followed by Financials and Consumer Discretionary.
On the sell side, the largest reduction was Marathon Petroleum, an estimated $73K trimmed.
- Accretive Wealth Partners's largest Q1 2024 buy was Humana: 3,149 shares worth $1.01M.
- Accretive Wealth Partners added most to Apple in Q1 2024, an estimated $3.4M increase.
- Accretive Wealth Partners's biggest Q1 2024 reduction was Marathon Petroleum, cutting an estimated $73K.
- Accretive Wealth Partners fully exited CVS Health in Q1 2024, selling an estimated $1.36M.
- Accretive Wealth Partners's ten largest holdings make up 35% of its $226M portfolio in Q1 2024.
- Accretive Wealth Partners opened 11 new positions and closed 3 in Q1 2024.
- Accretive Wealth Partners's portfolio value rose 8.6% quarter-over-quarter to $226M.
Based on Accretive Wealth Partners's 13F filing for Q1 2024, filed 6 May 2024.